This was the stock's second consecutive day of gains.

A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month.

Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.

J&J has a multi-year head start, but Gilead believes it can win market share by delivering a drug with better safety and at ...

A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent ...

By Deena Beasley (Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more ...

Spoiler alert! Here's how Hulu's "The Handmaid's Tale" ends after six long seasons of June (Elisabeth Moss) in Gilead.

(Reuters) -Gilead Sciences says it still plans to supply its twice-yearly injection for preventing HIV infection in ...